Association Between Apolipoprotein E Polymorphism and Subclinic Atherosclerosis in Patients with Type 1 Diabetes Mellitus

Mehmet Emre Atabek1, Yusuf Özkul2, Beray Selver Eklioglu1, Selim Kurtoglu3, Murat Baykara4

1Selçuk University, Meram Faculty of Medicine, Department of Pediatric Endocrinology, Konya, Turkey
2Erciyes University, School of Medicine, Department of Genetics, Kayseri, Turkey
3Erciyes University, School of Medicine, Department of Pediatric Endocrinology, Kayseri, Turkey
4Erciyes University, School of Medicine, Department of Radiology, Kayseri, Turkey

Introduction

Diabetes mellitus (DM) is a complex disorder characterized by hyperglycemia. Cardiovascular disease is frequent in type 1 DM. The most important cause of morbidity and mortality in type 1 DM is atherosclerosis (1).

It has recently been shown that ultrasonography is a powerful non-invasive tool for evaluating early atherosclerotic lesions in the carotid artery (2,3,4). Increased carotid artery intima-media thickness (CA-IMT) is significantly related to cardiovascular risk factors and to carotid plaque, which is a more advanced atherosclerotic lesion. Increased CA-IMT may be observed even in adolescents with type 1 DM (5).

Apolipoprotein E (Apo E) polymorphism has been accused as being the responsible factor for development of atherosclerosis. Apo E plays a major role in lipid metabolism and has a high affinity for low-density lipoprotein (LDL) receptors (6). It has three common isoforms (E2, E3, and E4) encoded by three alleles (e2, e3, e4) in exon 4 of the Apo E gene. Apo E3 is the most common form (7).

The aim of our present study was to assess the atherosclerosis indices and CA-IMT in patients with type 1 DM and also to investigate the relationship between Apo E polymorphism and these factors. Especially, we aimed to find which Apo E polymorphism is associated with atherosclerosis.
Methods

This study was performed in the Pediatric Endocrinology Department at Erciyes University School of Medicine. The study was approved by the local ethics committee of Erciyes University and was conducted in accordance with the guidelines proposed in the Declaration of Helsinki. Signed informed consent was obtained from the parents.

Seventy-four patients (38 female, 36 male) with type 1 DM participated in this study. Sex, age, anthropometric parameters, blood pressure (BP), lipid profiles, daily insulin dose, urinary albumin excretion, glycated hemoglobin (HbA1c) level, common carotid artery functions and Apo E genotype were determined in each patient.

Patients under 19 years of age, with type 1 DM using insulin therapy, and who had been followed for at least 1 year were planned to be included in the study; thus, 38 female and 36 male patients aged between 8 and 18 were recruited. None of the patients had diseases such as hypertension, hyperlipidemia and other cardiovascular diseases known to affect the common carotid artery functions, and no patient was under any medication other than antidiabetic drugs. None of the patients had ever smoked.

Twenty-four-hour urine samples were collected and analyzed for presence of albuminuria after excluding proteinuria due to urinary tract infection. Microalbuminuria was defined as a 24-h urinary albumin excretion of >30 mg. A urinary albumin excretion exceeding 300mg/24h in at least two urine samples evaluated within a 12-week interval was accepted to indicate clinical nephropathy. None of the patients were diagnosed to have renal disease unrelated to diabetes during their follow-up.

Hyperlipidemia was defined as a serum lipid level higher than the 95th percentile for age and sex. BP was measured with a standard mercury sphygmomanometer after the subjects had rested for at least 10 min. Subjects were considered as hypertensive if their systolic BP and/or their diastolic BP were above the 95th percentile for age and sex, or if they were receiving antihypertensive treatment. Anthropometric measurements were performed by the same clinician in all subjects. Height was measured using a wall-mounted stadiometer and weight was determined using a balance scale with the subject dressed only in light underwear and wearing no shoes. Body mass index (BMI) was calculated as the ratio of weight (kg) to the square of height (m²). Hip circumference and waist circumference were measured and recorded.

Blood samples were collected after a minimum eight hours of fasting. Serum lipid concentrations and urine microalbumin levels were assayed using the Konelab 60i analyser (Konelab, Espoo, Finland). Plasma HbA1c concentrations were assayed by automated high-performance liquid chromatography (reference rate <6%).

Determination of Apo E polymorphism

To perform Apo E genotyping assays, venous blood was collected from all subjects in sterile EDTA 4-mL tubes. Genomic DNA was extracted from whole blood using High Pure PCR Template Preparation kits (Roche Diagnostics, GmbH Mannheim, Germany). Apo E polymorphism was determined by quantitative real-time reverse transcription-polymerase chain reaction, which is a well-established and validated method (LightCycler Apo E Mutation Detection Kit; Roche Diagnostics) (Ballerni et al 2002). A 265-bp fragment of Apo E gene was amplified with specific primers from human genomic DNA. The amplicon was detected by fluorescence using a pair of hybridization probes. The hybridization probes were also used to determine the genotype by performing melting curve analysis after the amplification cycles were completed.

Common carotid artery ultrasonography

All examinations were done by the same sonographer, who was blinded to the participant’s case status and risk factor levels. High-resolution B-mode ultrasonography of the right common carotid artery was performed with SSA-370A Power Vision 6000 Digital Ultrasound System equipped with a 7.5 MHz linear transducer (Toshiba Corporation, Tokyo). Subjects were kept in a quiet, dark, temperature-controlled room and rested in supine position for about 15-20 minutes. They were examined in the supine position with the head slightly extended and turned slightly to the left. Longitudinal images of the common carotid artery were obtained by combined B-mode and color Doppler ultrasound examinations. IMT of the posterior (far) wall of the common carotid artery was measured with the electronic calipers of the machines, as described by Pignoli et al (8). On a longitudinal, 2-dimensional ultrasound image of the carotid artery, images of the posterior wall of the carotid artery are displayed as 2 bright white lines separated by a hypoechoic space. The distance between the leading edge of the first bright line of the far wall and the leading edge of the second bright line indicates the IMT. The IMT was measured during end diastole. The IMT measurements were performed on-line. The mean IMT was calculated by taking the average value of three measurements obtained from the common carotid artery; 20 mm below the carotid bulb.

Statistics

Data analysis was performed using SPSS for Windows 11.5 package program. Kolmogorov Smirnov test was used to
determine whether continuous variables were normally distributed. Descriptive statistics for continuous measurement variables were shown as mean±standard deviation or median (interquartile width). Nominal variables were presented as number of cases as well as in percentages (%).

Significance of difference in terms of averages was evaluated between the groups. When the number of independent groups was limited to two, the Student’s t-test was used. The significance of the differences between more than two groups was evaluated in the parametric one-way analysis of variance (one-way ANOVA). Significance of differences in terms of medians was evaluated between the groups. When the number of independent groups was two, the Mann-Whitney U-test was used. The significance of the differences between more than two groups was evaluated applying the nonparametric one-way ANOVA (Kruskal-Wallis).

In instances of significant results with the Kruskal-Wallis test, nonparametric multiple comparison tests were used to identify the conditions that caused the difference.

Nominal variables were evaluated with Pearson’s chi-square test. Statistically significant correlations between continuous variables were assessed by the Spearman correlation test. All possible risk factors thought to influence the atherosclerosis indicators were adjusted. The multivariate linear regression analysis was applied to detect any statistically significant difference between genotypes. Regression coefficient for each variable was calculated with 95% confidence interval. LDL cholesterol, high-density lipoprotein (HDL) cholesterol and CA-IMT variables were not normally distributed and logarithmic transformation was performed for the linear regression analysis.

A p-value of less than 0.05 was considered statistically significant for the results.

**Table 1. Clinical findings according to genotypes**

| Variables               | E3/E3   | E4/E4   | E3/E4   | E2/E3   | p-value |
|-------------------------|---------|---------|---------|---------|---------|
| Age (years)             | 14.2±2.2| 15.2±1.8| 14.5±2.2| 13.7±2.7| 0.476   |
| Gender                  |         |         |         |         | 0.235   |
| Female                  | 11 (52.4%)| 5 (83.3%)| 14 (53.8%)| 8 (38.1%)|         |
| Male                    | 10 (47.6%)| 1 (16.7%)| 12 (46.2%)| 13 (61.9%)|         |
| BMI                     | 20.1±2.9| 22.1±2.0| 20.8±3.0| 19.0±2.6| 0.060   |
| Waist-to-hip ratio      | 0.8±0.0| 0.8±0.0| 0.8±0.0| 0.8±0.0| 0.116   |
| Duration of diabetes (years) | 4.0 (4.0) | 4.3 (5.3) | 6.0 (3.5) | 5.0 (3.8) | 0.061   |
| Daily insulin dose (U/day) | 1.0 (0.3) | 1.2 (0.5) | 0.9 (0.2) | 1.0 (0.3) | 0.608   |

BMI: body mass index

**Table 2. Laboratory findings according to genotypes**

| Variables               | E3/E3   | E4/E4   | E3/E4   | E2/E3   | p-value |
|-------------------------|---------|---------|---------|---------|---------|
| HbA1c (%)               | 10.1±3.1| 11.0±2.0| 9.5±1.8| 10.1±2.4| 0.523   |
| Microalbuminuria (mg)   | 7.8 (9.5)| 10.0 (15.2)| 7.3 (14.9)| 7.8 (12.5)| 0.970   |
| Systolic blood pressure (mm/Hg) | 115.0 (5.0) | 120.0 (3.8) | 115.0 (10.0)| 110.0 (10.0)| 0.019   |
| Diastolic blood pressure (mm/Hg) | 70.0 (5.0) | 70.0 (3.8) | 70.0 (6.3) | 70.0 (5.0) | 0.665   |
| Total Cholesterol (mg/dL) | 145.1±26.8| 141.0±18.9| 160.0±26.8| 147.9±21.3| 0.132   |
| Triglyceride (mg/dL)     | 95.0 (63.0)| 85.5 (31.3)| 97.5 (53.5)| 70.0 (29.0)| 0.037   |
| HDL Cholesterol (mg/dL)  | 48.0 (30.0)| 40.5 (35.5)| 52.5 (21.3)| 55.0 (12.5)| 0.234   |
| LDL Cholesterol (mg/dL)  | 66.1 (28.2)| 78.0 (19.7)| 85.6 (29.9)| 68.8 (18.0)| 0.089   |
| CA-IMT (cm)              | 0.5 (0.0) | 0.6 (0.1) | 0.5 (0.0) | 0.4 (0.0) | <0.001   |

HbA1c: glycated hemoglobin, HDL: high-density lipoprotein, LDL: low-density lipoprotein, CA-IMT: carotid artery intima media thickness
Results

The clinical and laboratory characteristics and CA-IMT measurements of the patients according to Apo E genotypes are shown in Tables 1 and 2. Systolic BP, triglyceride level and CA-IMT were significantly different between genotypes. Systolic BP and CA-IMT were higher in E4/E4 genotype, while triglyceride level was higher in E3/E4 genotype.

There were no significant differences in CA-IMT measurements, total cholesterol, triglyceride and HDL levels between girls and boys. The p-values were 0.106, 0.105, 0.799 and 0.559, respectively.

The correlations between clinical characteristics and total cholesterol, HDL cholesterol, LDL cholesterol.

Correlation coefficients, significance levels between CA-IMT measurement and clinical characteristics are shown in Table 3. CA-IMT was positively correlated with age, BMI, waist-to-hip ratio and systolic BP.

According to univariate analysis, when adjusting for all risk factors, genotypes did not differ for total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides (p>0.05). However, E3/E3, E3/E4 and E4/E4 genotypes were found to be associated with increased CA-IMT (p<0.001).

Discussion

Type 1 DM is associated with a two- to fourfold higher risk of coronary artery disease (9). The increase of cardiovascular risk in this population cannot be explained only by traditional risk factors.

Studies on potential gene polymorphisms that can directly affect the development of atherosclerosis are rare (10). Apo E gene polymorphism is thought to cause an alteration in lipoprotein metabolism. Apo E-deficient mice have been reported to develop severe dyslipidemia and atherosclerotic lesions (11). The E4 allele has been found to be related with LDL-cholesterol levels. However, the effects of Apo E polymorphism on triglyceride and HDL cholesterol levels have not been resolved (12).

Studies have shown that increased CA-IMT is a predictor of atherosclerosis. Associations between Apo E alleles and cardiovascular risk have also been reported (13,14). Wohlin et al (15) found increased CA-IMT in Apo E4 homozygous genotype. In the ARIC and CUDAS studies, E4/E4-homozygous men were reported to have a significantly increased CA-IMT (16,17). In the Rotterdam study, men with the e4/e4 genotype had slightly, but not significantly increased CA-IMT (18). These studies were performed in elderly persons and only in men. To our knowledge, there are no studies assessing the relationship between CA-IMT and Apo E polymorphism in children with type 1 DM. In our study, we found higher CA-IMT in the E4/E4 homozygous genotype subjects.

It has been reported that the E4 and E3 alleles increase plasma cholesterol concentration, while E2 alleles have an opposite effect (3,19). It was also reported that subjects with E4 allele had higher lipid levels, especially LDL cholesterol levels (20). Tascilar et al (20) and Fernandez et al (21) showed that the E4 allele was associated with elevated LDL cholesterol. Benne et al (22) reported that Apo E genotypes were related to LDL levels and coronary risk. E2 carriers were found to have 20% reduced coronary disease risk, while E4 carriers had increased risk. In this study, we found no significant association between LDL cholesterol, HDL cholesterol, total cholesterol and Apo E genotypes. Only triglyceride levels were significantly different between Apo E genotypes and higher in E3/E4 allele. We think that these results may be associated with the smallness of our sample.

In some populations, a stronger association between Apo E 4 allele and coronary artery disease was described for men (23). However, a meta-analysis study revealed that Apo E genotypes were not related to gender (22). No gender difference was found in the present study.

Type 1 DM is an important risk factor for the development of cardiovascular diseases (24). Carotid artery stiffness and IMT measured by ultrasonography are correlated with atherosclerosis and cardiovascular diseases in patients with type 1 DM (25). Several groups have demonstrated that patients with type 1 DM have higher mean CA-IMT. Increased CA-IMT in children with type 1 DM may be an early step in the development of atherosclerosis. Yavuz et al (26) and Gunczler et al (27) found no increase of CA-IMT in children with type 1 DM. However, Yamasaki et al (28) Jarvisalo et al

Table 3. Correlation coefficients, significance levels between CA-IMT measurements and clinical characteristics

| Variables | CA-IMT | r | p  |
|-----------|--------|---|----|
| Age (years) | 0.231 | 0.048 |
| Duration of diabetes (years) | 0.198 | 0.091 |
| Daily insulin dose (U/day) | 0.075 | 0.525 |
| HbA1c (%) | 0.042 | 0.725 |
| Microalbuminuria (mg) | 0.082 | 0.485 |
| BMI | 0.344 | 0.003 |
| Waist-to-hip ratio | 0.273 | 0.019 |
| Systolic blood pressure (mm/Hg) | 0.380 | <0.001 |
| Diastolic blood pressure (mm/Hg) | 0.206 | 0.078 |

HbA1c: glycated hemoglobin, BMI: body mass index, CA-IMT: carotid artery intima media thickness
(29) and Vastagh I et al (30) reported that CA-IMT values were significantly higher in children with type 1 DM. Jarvisalo et al (29) also showed that type 1 DM was an independent risk factor for high CA-IMT. Similarly, we demonstrated increased CA-IMT in type 1 DM previously (31,32).

It is known that familial hypercholesterolemia and borderline hypertension are related to high IMT (29,33). Also, BMI was reported to be correlated with CA-IMT (34). Childhood obesity seems to contribute to the development and progression of early atherosclerosis. Zhu et al (35) found higher CA-IMT in obese Chinese school children. We also found that CA-IMT positively correlated with BMI, waist-to-hip ratio, and systolic BP in our study.

Our study demonstrates the association of Apo E4/E4 polymorphism with CA-IMT and coronary artery disease in type 1 diabetes patients and this association is independent of anthropometric and metabolic measurements. Apo E4/E4 allele might be the major genetic risk factor for increased CA-IMT and atherosclerosis in children with type 1 DM.

References

1. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
2. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.
3. Puja A, Gnasso A, Iraace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care 1994;17:1330-1336.
4. Lehmann ED, Riley WA, Clarkson P, Gosling RG. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997;350:114-119.
5. Atabek ME, Kurtoglu S, Demir F, Baykara K. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr 2004;93:1052-1057.
6. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-2192.
7. Brouwer DA, van Doormaal JJ, Muskiet FA. Clinical chemistry of common Apolipoprotein E isoforms. J Chromatogr B Biomed Appl 1996;678:23-41.
8. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399-1406.
9. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboli P, Michel G, Manes C, Fuller JH. EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care 2004;27:530-537.
10. Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The Apolipoprotein E ε4 allele increases the odds of chronic cerebral infarction detected at autopsy in older persons. Stroke 2005;36:954-959.
11. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-140.
12. Han Z, Heath SC, Shmulewitz D, Li W, Auerbach SB, Blundell ML, Lehner T, Ott J, Stoffel M, Friedman JM, Breslow JL. Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia. Am J Med Genet 2002;110:234-242.
13. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
14. Sloozer R, Ordovas JM, Cupples LA, Fox CS, Polak JF, Wolf PA, D’Agostino RA Sr, O'Donnell CJ. Association of APOE genotype with carotid atherosclerosis in men and women: the Framingham Heart Study. J Lipid Res 2004;45:1868-1875.
15. Wohlin M, Sundström J, Lannefelt L, Axelsson T, Syvänen AC, Andrien B, Basu L, Lind L. Apolipoprotein E epsilon 4 genotype is independently associated with increased intima-media thickness in a recessive pattern. Lipids 2007;42:451-456.
16. Belliby JP, Hunt CC, Palmer LJ, Chapman CM, Burley JP, McQuillan BM, Thompson PL, Hung J, Perth Carotid Ultrasound Disease Assessment Study. Apolipoprotein E gene polymorphisms are associated with carotid plaque formation but not with intima-media wall thickening: results from the Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Stroke 2003;34:869-874.
17. Volck KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, Ballantyne CM, Boerwinkle E. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006;164:342-348.
18. Bennet AP, Bots ML, Havekes LM, del Sol AI, Cruts M, Grobbe DE, Hofman A, Van Broeckhoven C, Witteman JC, van Duijn CM. Apolipoprotein E and carotid artery atherosclerosis: the Rotterdam study. Stroke 2001;32:1947-1952.
19. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
20. Tascilar N, Dursun A, Ankarali H, Mungan G, Sumbuloglu V, Ekem S, Bozdogan S, Baris S, Aciman E, Cabuk F. Relationship of Apo E polymorphism with lipoprotein(a), VLDL, triglycerides and C-reactive protein in patients with familial hypercholesterolemia. Vasc Med 2001;6:351-355.
21. Biasucci L, Ordi-Ros J, Pascual J, Rodriguez-Viciana C, Rodríguez-Roisín R, Martínez-López E, De la Torre-Vázquez C, Muntaner C. ApoE polymorphism and coronary heart disease: the Rotterdam study. Stroke 2001;32:1947-1952.
22. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Vrana B, de Faire U, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: an independent risk factor for myocardial infarction in the Copenhagen City Heart Study. J Am Coll Cardiol 2007;20:217-221.
23. Fernández-Mestre MT, Yehirobi C, Montagnani S, Balbas O, Layrisse Z. Genetic variability of Apolipoprotein E in different populations from Venezuela. Dis Markers 2005;21:15-19.
24. Breslow JL, Raitakari M, Toikka JO, Voutilainen E, Kangas H, Järvisalo MJ, Raitakari OT. Endothelial Dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004;109:1750-1755.
25. Parikh A, Sochett EB, McCrindle BW, Dipchand A, Daneman A, Daneman D. Carotid artery distensibility and function in adolescents with type 1 diabetes. J Pediatr 2000;137:465-469.

26. Yavuz T, Akcay A, Omeroglu RE, Bundak R, Sukur M. Ultrasonic evaluation of early atherosclerosis in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:1131-1136.

27. Gunczler P, Lanes R, Lopez E, Esaa S, Villarroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness and lipoprotein (a) levels in children and adolescents with type 1 diabetes mellitus of short duration. J Pediatr Endocrinol Metab 2002;15:181-186.

28. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y, Morishima T, Kamada T. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 1994;43:634-639.

29. Järvisalo MJ, Putto-Laurila A, Jartti L, Lehtimäki T, Solakivi T, Rönnemaa T, Raitakari OT. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002;51:493-498.

30. Vastagh I, Horváth T, Nagy G, Varga T, Juhász E, Juhász V, Kollai M, Berczki D, Somogyi A. Evolution and predictors of morphological and functional arterial changes in the course of type 1 diabetes mellitus. Diabetes Metab Res Rev 2010;26:646-655.

31. Atabek ME, Pirgon O, Kurtoglu S, Imamoglu H. Evidence for an association between type 1 diabetes and premature carotid atherosclerosis in childhood. Pediatr Cardiol 2006;27:428-433.

32. Atabek ME, Kurtoglu S, Pirgon O, Baykara M. Arterial wall thickening and stiffening in children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2006;74:33-40.

33. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimalmedial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003;111:61-66.

34. Markus RA, Mack WJ, Azen SP, Hodis HN. Influence of lifestyle modification on atherosclerotic progression determined by ultrasonographic change in the common carotid intima-media thickness. Am J Clin Nutr 1997;65:1000-1004.

35. Zhu W, Huang X, He J, Li M, Neubauer H. Arterial intima-media thickening and endothelial dysfunction in obese Chinese children. Eur J Pediatr 2005;164:337-344.